推荐产品
等级
pharmaceutical primary standard
API类
mupirocin
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
格式
neat
SMILES字符串
[H][C@@]1(CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O)C[C@@H]2O[C@@]2([H])[C@@H](C)[C@H](C)O
InChI
1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
InChI key
MINDHVHHQZYEEK-HBBNESRFSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Mupirocin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
生化/生理作用
Antibiotic; inhibits isoleucyl-tRNA synthetase (IRS).
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 25(2), 587-592 (2009-08-15)
Recently, there have been increasing concerns about the emergence of mupirocin resistance and increased infections due to lowered inhibition of Staphylococcus aureus. We conducted this systemic analysis to find out whether the application of mupirocin was effective for the prevention
The Journal of antimicrobial chemotherapy, 41(1), 11-18 (1998-03-25)
Mupirocin was introduced into clinical practice in the UK in 1985, and has proved to be an extremely effective treatment of skin infections and one of the most successful topical antibiotics for the clearance of nasal Staphylococcus aureus isolates including
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37(7), 933-938 (2003-09-18)
Most Staphylococcus aureus infections are endogenously acquired, and treatment of nasal carriage is one potential strategy for prevention. We critically appraised the published evidence regarding the efficacy of intranasal mupirocin for eradication of S. aureus nasal carriage and for prophylaxis
Journal of chemotherapy (Florence, Italy), 11(5), 331-337 (2000-01-13)
Mupirocin (pseudomonic acid A) is indicated for primary and secondary skin infections, and for the eradication of nasal colonization of Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This paper reviews the mechanisms by which resistance to mupirocin can develop, discusses
The Journal of antimicrobial chemotherapy, 64(1), 9-15 (2009-05-20)
Staphylococcus aureus in the nose is a risk factor for endogenous staphylococcal infection. UK guidelines recommend the use of mupirocin for nasal decolonization in certain groups of patients colonized with methicillin-resistant S. aureus (MRSA). Mupirocin is effective at removing S.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门